Approval · Notice of Compliance 35103 · 2025
NETSPOT: Notice of Compliance 35103
Issued March 31, 2025
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 35103
- Date
- March 31, 2025
- Company
- Novartis Pharmaceuticals Canada Inc.Montreal, Quebec, Canada
- Product type
- Radiopharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Drug product manufacturing process change
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| NETSPOT | Not yet assigned | — |
Medicinal ingredients
- OXODOTREOTIDE 40 MCG per VIAL